Zobrazeno 1 - 10
of 476
pro vyhledávání: '"V Upreti"'
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 12, Iss 2, Pp 250-260 (2023)
Abstract Talimogene Laherparepvec (T‐VEC) is a first‐in‐class oncolytic virotherapy approved for the treatment of unresectable melanoma recurrent after initial surgery. Biodistribution data from a phase II study was used to develop a viral kine
Externí odkaz:
https://doaj.org/article/d1b7ce925d2e4b18b4554c4442799b30
Autor:
Tong-yuan Yang, Manuela Braun, Wibke Lembke, Fraser McBlane, John Kamerud, Stephen DeWall, Edit Tarcsa, Xiaodong Fang, Lena Hofer, Uma Kavita, Vijay V. Upreti, Swati Gupta, LiNa Loo, Alison J. Johnson, Rakesh Kantilal Chandode, Kay-Gunnar Stubenrauch, Maya Vinzing, Cindy Q. Xia, Vibha Jawa
Publikováno v:
Molecular Therapy: Methods & Clinical Development, Vol 26, Iss , Pp 471-494 (2022)
Immunogenicity has imposed a challenge to efficacy and safety evaluation of adeno-associated virus (AAV) vector-based gene therapies. Mild to severe adverse events observed in clinical development have been implicated with host immune responses again
Externí odkaz:
https://doaj.org/article/1b85bb2274f44631a3d3b829f5704b0f
Autor:
Johannes Kast, Saeideh Nozohouri, Di Zhou, Marc R. Yago, Po‐Wei Chen, Malidi Ahamadi, Sandeep Dutta, Vijay V. Upreti
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 9, Pp 2057-2074 (2022)
Abstract Advances in immuno‐oncology have provided a variety of novel therapeutics that harness the innate immune system to identify and destroy neoplastic cells. It is noteworthy that acceptable safety profiles accompany the development of these t
Externí odkaz:
https://doaj.org/article/8506c62661e546e89357bc447bb8e20a
Autor:
Yuan Chen, Tamara D. Cabalu, Ernesto Callegari, Heidi Einolf, Lichuan Liu, Neil Parrott, Sheila Annie Peters, Edgar Schuck, Pradeep Sharma, Helen Tracey, Vijay V. Upreti, Ming Zheng, Andy Z.X. Zhu, Stephen D. Hall
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 9, Pp 685-695 (2019)
Regulatory agencies currently recommend itraconazole (ITZ) as a strong cytochrome P450 3A (CYP3A) inhibitor for clinical drug–drug interaction (DDI) studies. This work by an International Consortium for Innovation and Quality in Pharmaceutical Deve
Externí odkaz:
https://doaj.org/article/a909582f81534613a6810cda695e685b
Autor:
Marc R. Yago, Khamir Mehta, Maitreyee Bose, Sharvari Bhagwat, Vivek S. Chopra, Sandeep Dutta, Vijay V. Upreti
Publikováno v:
Clinical Pharmacokinetics. 62:779-788
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a3b77a266089f56d4cd1f1e22c6ba5e
https://doi.org/10.1007/s40262-023-01242-6
https://doi.org/10.1007/s40262-023-01242-6
Autor:
Ben Tran, Richard D. Carvajal, Aurelien Marabelle, Sandip Pravin Patel, Patricia M. LoRusso, Erik Rasmussen, Gloria Juan, Vijay V. Upreti, Courtney Beers, Gataree Ngarmchamnanrith, Patrick Schöffski
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 6, Iss 1, Pp 1-9 (2018)
Abstract Background This open-label, first-in-human, phase 1 study evaluated the safety, pharmacokinetics, pharmacodynamics, and maximum tolerated dose (MTD) of AMG 228, an agonistic human IgG1 monoclonal antibody targeting glucocorticoid-induced tum
Externí odkaz:
https://doaj.org/article/c2fbc142a7e5490699bc7de71158c8cb
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Stergios J. Moschos, Shahneen Sandhu, Karl D. Lewis, Ryan J. Sullivan, Igor Puzanov, Douglas B. Johnson, Haby A. Henary, Hansen Wong, Vijay V. Upreti, Georgina V. Long, Keith T. Flaherty
Publikováno v:
Investigational New Drugs. 40:1051-1065
Background Targeting the MDM2-p53 interaction using AMG 232 is synergistic with MAPK inhibitors (MAPKi) in preclinical melanoma models. We postulated that AMG 232 plus MAPKi is safe and more effective than MAPKi alone in TP53-wild type, MAPKi-naïve
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5c5a9d4435c509fa8da92fc8a62a3144
https://doi.org/10.1007/s10637-022-01253-3
https://doi.org/10.1007/s10637-022-01253-3